Comments
Strides Arcolab has received approval from the US health regulator for its Benzonatate softgel capsules used for treating cough caused by cold, and other breathing problems such as pneumonia and asthma.
The product will be launched immediately in the US market, Strides Arcolab said in a filing to the BSE.
The company has received approval from the United States Food and Drug Administration (USFDA) for Benzonatate softgel capsules in the strengths of 100 mg and 200 mg, it added.
“According to IMS data, the US market for Benzonatate is approximately USD 41 million,” Strides Arcolab said.
The product will be manufactured at the company’s oral dosage facility at Bengaluru and marketed by the company in the US, it added.
Shares of Strides Arcolab were trading at Rs 1,272.70 per scrip on BSE, up 1.18 per cent from their previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.